Related Experiment Video
Updated: Aug 14, 2026
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
Published on: June 9, 2022
HCV virological assessment
1Liver Unit, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain. xforns@clinic.ub.es
Insights
Virological assays for Hepatitis C Virus (HCV) infection are crucial for diagnosis and treatment. Special considerations are needed for co-infected patients due to unique characteristics impacting assay interpretation.
Area of Science:
- Virology
- Infectious Diseases
- Immunology
Background:
- Virological assessment of Hepatitis C Virus (HCV) infection is vital for diagnosis and therapeutic decisions.
- Diagnostic assays include antibody detection, viral load quantification, and genotyping.
- Co-infected patients (HCV and HIV) present unique challenges in assay interpretation due to immune status and higher viral loads.
Purpose of the Study:
- To review the application and interpretation of virological assays in HCV mono-infected versus HCV/HIV co-infected patients.
- To highlight differences in assay performance and utility in co-infected individuals.
- To provide guidance on selecting appropriate assays for co-infected populations.
Main Methods:
- Review of existing literature on HCV virological assays.
- Comparison of assay sensitivity and specificity in mono-infected and co-infected cohorts.
- Analysis of factors influencing assay interpretation in co-infected patients.
Main Results:
- Last-generation anti-HCV antibody tests show similar sensitivity in both groups.
- HCV-RNA testing is valuable for diagnosing liver disease in anti-HCV negative individuals.
- Sequence analysis is preferred for HCV genotyping in co-infected patients due to lower sensitivity of serotyping assays.
- Higher HCV-RNA concentrations in co-infected patients necessitate assays with a wide dynamic range for treatment monitoring.
Conclusions:
- Virological assay interpretation requires specific considerations in HCV/HIV co-infected patients.
- Appropriate assay selection is critical for accurate diagnosis, monitoring, and guiding therapy in co-infected individuals.
- Further research may be needed to optimize diagnostic and monitoring strategies for this population.
Abstract:
Virological assessment of HCV infection relies on a series of assays that are essential for diagnostic purposes and to adopt therapeutic decisions. Diagnostic assays can be classified in three groups: assays that are designed to detect specific antibodies to HCV; techniques that detect and quantify viral load; and tests aimed at determining the infecting HCV type. In general, the use of these assays is similar in HCV infected patients as in those co-infected with HCV and HIV. Co-infected patients, however, have some inherent characteristics (deficient immune status, high HCV-RNA concentrations, particular genotype distribution, low response to antiviral therapy) that make the interpretation of such assays slightly different. Regarding assays to detect antibodies to HCV, last generation tests have a similar sensitivity in mono-infected and co-infected individuals. HCV-RNA testing might be helpful in anti-HCV negative individuals with clinical or analytical suspicion of liver disease. Genotype determination in patients co-infected with HCV and HIV should be performed by methods relying on sequence analysis, since serotyping assays have shown a lower sensitivity in co-infected cohorts. HCV-RNA concentration is a strong predictor of response to therapy. Due to the higher viral load of co-infected patients compared to HCV mono-infected individuals, those assays with a wide dynamic range seem more appropriate to monitor viral load during treatment.
Related Concept Videos
01:28Viral Hepatitis I: Introduction
01:25Hepatitis